Ecron Acunova, the full-service contract research organisation (CRO) based in Bangalore, India, has further bolstered its international credentials by acquiring a majority stake in aCROnordic, a CRO operating across the Nordic region.

With US and European headquarters in Princeton and Frankfurt (Germany) respectively, Ecron Acunova already has a presence in 19 Western and Eastern European countries as well as seven markets across South and South East Asia.

aCROnordic provides a full range of CRO services to the pharmaceutical and medical device industries, with particular expertise in neurology, oncology and cardiology. Its headquarters are in Scion-DTU near Copenhagen, the largest university science park in Denmark, while its field of operations spans Denmark, Sweden, Finland and Norway.

No financial details were disclosed on the deal with Ecron Acunova, nor the size of the majority stake involved. Søren Strøh, founder and previous owner of aCROnordic, continues in the role of chief executive officer for the Nordic region.

D A Prasanna, founder and chairman of Ecron Acunova, noted that the recent shift towards strategic outsourcing in clinical research called for a “more global presence of preferred provider CROs”.

The merger of Ecron Acunova and aCROnordic, both of them with “decades of track record, an excellent reputation and deep local knowledge in their geographies”, would provide “substantial synergy to both of us for serving our clients’ needs”, he added.

According to Strøh, aCROnordic sees the merger as “an opportunity to fulfil our dream of being the first Nordic development CRO in an international organisation”.